Gilead Sciences, Inc. (NASDAQ:GILD) has been given a $86.00 target price by investment analysts at Berenberg Bank in a report released on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s price target suggests a potential upside of 15.14% from the stock’s previous close.

Several other brokerages have also issued reports on GILD. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $83.00 target price on shares of Gilead Sciences in a research note on Thursday, July 27th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research note on Thursday, July 27th. Eleven research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $80.83.

Shares of Gilead Sciences (GILD) traded up 1.16% during trading on Tuesday, hitting $75.56. 7,603,587 shares of the company’s stock were exchanged. The stock has a market cap of $98.68 billion, a PE ratio of 8.21 and a beta of 1.21. The stock’s 50-day moving average price is $72.97 and its 200-day moving average price is $68.86. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $82.07. Gilead Sciences also was the target of unusually large options trading on Monday. Stock investors purchased 19,878 put options on the stock. This is an increase of approximately 209% compared to the average daily volume of 6,434 put options.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.08 earnings per share. On average, equities analysts expect that Gilead Sciences will post $8.74 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/29/berenberg-bank-analysts-give-gilead-sciences-inc-gild-a-86-00-price-target.html.

In related news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 206,666 shares of company stock valued at $15,223,184. 1.30% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Hall Laurie J Trustee increased its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the period. Dubuque Bank & Trust Co. increased its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the period. Penserra Capital Management LLC increased its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. Finally, Webster Bank N. A. increased its position in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares during the period. Institutional investors own 74.04% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.